Curative Biotechnology (CUBT) Stock Price, News & Analysis

Company Overview

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

Key Stats

• Today's Range: $0.0095 to $0.0118
• 50-Day Range: $0.0080 to $0.0172
• 52-Week Range: $0.00 to $0.04
• Volume: 410,076 shs
• Average Volume: 196,202 shs
• Market Capitalization: $8.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CUBT Stock Analysis - Frequently Asked Questions

How have CUBT shares performed this year?

Curative Biotechnology's stock was trading at $0.0213 at the start of the year. Since then, CUBT stock has decreased by 46.0% and is now trading at $0.0115.
View the best growth stocks for 2024 here.

How do I buy shares of Curative Biotechnology?

Shares of CUBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 10/04/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Miscellaneous health & allied services, not elsewhere classified
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CUBT
• CUSIP: N/A
• CIK: 1400271
• Web: curativebiotech.com
• Phone: (561) 418-7725
• Fax: 866-900-1002
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 703,263,000
• Free Float: N/A
• Market Cap: $8.09 million
• Optionable: Not Optionable
• Beta: -17.59